Serum igG antibodies to GD1a and GM1 gangliosides in elderly people

   


1. Institute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Sofia, Bulgaria
Type: Clinical and diagnostic research
DOI: 10.18097/PBMC20166201093      UDK: 616.89      PubMed Id: 26973195
Year: 2016 vol: 62  issue:1  pages: 93-95
Abstract: Nowadays, the percentage of elderly people in society grows. Good nutrition and medical care help older people to have a normal life over 80 to 90 years. In the last ten years it is of critical importance to establish the clinical significance of serum IgG anti-GD1a and anti-GM1 ganglioside antibodies as potential biomarkers for neuronal damage in neurodegenerative diseases and immune-mediated neuropathies and demyelination. In the current study, the diagnostic values of IgG anti-GD1a and anti-GM1 antibodies were determined by the ELISA method in serum samples of 18 elderly patients (71-91 years). Significantly elevated serum IgG anti-GD1a and anti-GM1 antibodies titers were detected only in patients over 80 years. These data suggest that the immune-mediated neuropathies, neurodegeneration and demyelination in healthy elderly occur after 80 years old. Therefore, IgG anti-GD1a and anti-GM1 antibodies can serve as biomarkers, showing the nervous system dysfunction.
Download PDF:
Reference: Kolyovska V., Serum igG antibodies to GD1a and GM1 gangliosides in elderly people, Biomeditsinskaya khimiya, 2016, vol: 62(1), 93-95.
References
 2017(Vol:63)
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 2011(Vol:57)
 2010(Vol:56)
 2009(Vol:55)
 2008(Vol:54)
 2007(Vol:53)
 2006(Vol:52)
 2005(Vol:51)
 2004(Vol:50)
 2003(Vol:49)